Bookmark and Share

Transition Therapeutics (TTHI) to Present at the Jefferies 2011 Global Healthcare Conference

TORONTO, June 7, 2011 (GLOBE NEWSWIRE) — Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX:TTH) (Nasdaq:TTHI) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition, will be presenting at the Jefferies 2011 Global Healthcare Conference on Thursday June 9, 2011 at 1:30pm Eastern Time at the Grand Hyatt Hotel in New York City.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition’s lead product is ELND005 (AZD-103) for the treatment of Alzheimer’s disease and Transition also has an emerging pipeline of innovative preclinical and clinical drug candidates. The other drugs in the pipeline that the Company is developing are for anti-inflammatory and metabolic indications. Transition’s shares are listed on the NASDAQ under the symbol “TTHI” and the Toronto Stock Exchange under the symbol “TTH”. For additional information about the Company, please visit

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition’s management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition’s control and the risk factors and other cautionary statements discussed in Transition’s quarterly and annual filings with the Canadian commissions.

For further information on Transition, visit, or contact:

CONTACT: Dr. Tony Cruz
         Chairman & Chief Executive Officer
         Transition Therapeutics Inc.
         Phone: (416) 260-7770, x.223

         Elie Farah
         President & Chief Financial Officer
         Transition Therapeutics Inc.
         Phone: (416) 260-7770, x.203
Tuesday, June 7th, 2011 Uncategorized
Top Small Cap Market News